tiprankstipranks
Trending News
More News >
Judges Scientific PLC (GB:JDG)
LSE:JDG

Judges Scientific (JDG) AI Stock Analysis

Compare
28 Followers

Top Page

GB

Judges Scientific

(LSE:JDG)

Rating:70Neutral
Price Target:
8,796.00p
▲(12.77%Upside)
Judges Scientific's overall score is driven by strong financial performance and positive corporate events. Technical analysis shows moderate potential, but valuation concerns due to a high P/E ratio temper enthusiasm. Continued positive corporate actions and financial management are key strengths.
Positive Factors
Financial Performance
Judges' FY24 Results are in line with guidance and with JEFe, with the improvement in cash flow being the highlight.
Management Strength
There remains a strong management team in place.
Track Record
Judges has an impressive track record of value creation, margin expansion, and organic growth.
Negative Factors
Leadership Changes
It is disappointing to see Mark Lavelle depart, as he is very well-regarded and brought valuable experience and knowledge to Judges.
US Market Risks
There is little conviction around the growth/margin recovery needed to drive rerating of the shares, especially with downside risk in the US from research funding cuts and delayed customer investment decisions.
US Sales Risk
25% of sales in the US, with academia accounting for half, face downside risk from wider demand destruction.

Judges Scientific (JDG) vs. iShares MSCI United Kingdom ETF (EWC)

Judges Scientific Business Overview & Revenue Model

Company DescriptionJudges Scientific plc designs, manufactures, and sells scientific instruments. The company operates through two segments, Materials Sciences and Vacuum. It offers engineering teaching and research equipment for universities, colleges, schools, and research centers; and research and development systems for food, beverage, dairy, edible oil, and pharmaceutical industries. The company also provides LED illumination systems for bioscience and clinical microscopy; tensile testing, motion control, and specimen cooling for microscopy applications; automated measurement systems for a range of fibers; edge-welded metal bellows; and fire testing instruments, such as cone calorimeters, large scale calorimeters, NBS smoke chambers and oxygen index test, and related fire testing instruments. In addition, it offers equipment and software used for the computer-controlled testing of soils and rocks; film deposition systems; physical and chemical vapour deposition instruments; open flow cryocoolers for the X-ray diffraction market and crycoolers for cooling applications, such as radio astronomy; test equipment for the characterization of optical fibers; scientific instruments primarily used for electron microscopy sample preparation; scientific equipment used by electrophysiology and imaging researchers; and gas purifiers for metal analysis. Further, the company provides specialized calorimeters used for chemical and battery industries; sample heating and manipulation products for use in vacuum markets for materials research and production; and sheet metalwork services, including components and casting, fabrication, bespoke engineering solutions, as well as laser cutting and CNC machining services. The company operates in the United Kingdom, rest of Europe, North America, China, and internationally. Judges Scientific plc was incorporated in 2002 and is based in London, the United Kingdom.
How the Company Makes MoneyJudges Scientific makes money by acquiring and managing a portfolio of scientific instrument companies. The company's revenue model is centered around the sales of high-value, precision scientific instruments manufactured by its subsidiaries. These instruments are used by research institutions, laboratories, and industrial companies. Revenue is generated through the direct sale of these products, as well as through ongoing service and maintenance contracts. The company benefits from a diversified product range and customer base, reducing dependency on any single revenue stream. Additionally, it may engage in strategic partnerships to enhance its market reach and technological capabilities, although specific partnerships are not detailed.

Judges Scientific Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
135.60M136.10M113.21M91.29M79.86M82.50M
Gross Profit
65.40M93.60M21.01M15.34M10.02M14.35M
EBIT
27.00M21.60M21.13M15.25M9.96M14.35M
EBITDA
39.30M35.60M29.00M20.33M15.17M18.54M
Net Income Common Stockholders
14.90M9.50M12.50M12.68M8.22M11.38M
Balance SheetCash, Cash Equivalents and Short-Term Investments
15.73M13.70M20.83M18.41M15.52M14.12M
Total Assets
65.73M183.50M185.79M88.98M82.03M70.61M
Total Debt
15.03M65.30M59.95M21.32M26.37M18.90M
Net Debt
-701.00K51.60M39.12M2.91M10.85M4.77M
Total Liabilities
34.52M100.90M131.33M45.58M48.98M41.92M
Stockholders Equity
30.64M82.40M54.24M42.78M32.19M27.87M
Cash FlowFree Cash Flow
15.20M20.60M12.33M13.44M10.53M15.28M
Operating Cash Flow
21.30M26.50M20.22M16.89M11.79M16.58M
Investing Cash Flow
-11.70M-25.90M-51.11M-5.21M-12.67M-1.37M
Financing Cash Flow
-17.40M-7.60M33.21M-8.81M2.34M-16.76M

Judges Scientific Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7800.00
Price Trends
50DMA
7294.80
Positive
100DMA
7393.60
Positive
200DMA
8331.79
Negative
Market Momentum
MACD
187.63
Positive
RSI
57.28
Neutral
STOCH
52.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:JDG, the sentiment is Positive. The current price of 7800 is below the 20-day moving average (MA) of 8054.00, above the 50-day MA of 7294.80, and below the 200-day MA of 8331.79, indicating a neutral trend. The MACD of 187.63 indicates Positive momentum. The RSI at 57.28 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:JDG.

Judges Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
£110.49M20.728.61%1.91%-11.80%-32.11%
GBSXS
76
Outperform
£2.02B8.7417.33%4.08%-11.09%65.87%
GBRSW
74
Outperform
£1.91B19.5911.07%2.90%4.71%0.43%
71
Outperform
£643.84M26.278.07%1.80%-5.56%-27.87%
GBGHH
70
Outperform
£140.79M27.194.79%2.22%1.74%359.50%
GBJDG
70
Neutral
£525.16M50.4012.29%1.24%-1.84%9.56%
62
Neutral
$11.80B10.31-7.45%2.91%7.43%-7.78%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:JDG
Judges Scientific
8,000.00
-1,968.74
-19.75%
GB:GHH
Gooch & Housego
594.00
70.72
13.51%
GB:RSW
Renishaw
2,785.00
-1,104.30
-28.39%
GB:SOLI
Solid State
195.00
-102.60
-34.48%
GB:SXS
Spectris
3,204.00
51.77
1.64%
GB:DSCV
discoverIE Group plc
676.00
-28.57
-4.05%

Judges Scientific Corporate Events

Business Operations and Strategy
Judges Scientific Executives Participate in Share Incentive Plan
Neutral
Jun 9, 2025

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan involving several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. Each transaction was conducted on the London Stock Exchange, AIM Market, at a price of 7870.0p per share, reflecting the company’s commitment to aligning management interests with shareholder value.

The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

DividendsBusiness Operations and Strategy
Judges Scientific Allocates Shares to Employees Under Reward Scheme
Positive
Jun 4, 2025

Judges Scientific announced the acquisition of 28 ordinary shares at a price of 7875p per share, which have been allocated to employees under the company’s reward scheme. This move reflects the company’s ongoing strategy to enhance shareholder value through sustainable profit generation, debt reduction, organic growth, and dividends.

The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Shareholder MeetingsBusiness Operations and Strategy
Judges Scientific AGM Resolutions Passed Amid Shareholder Dissent
Neutral
May 23, 2025

Judges Scientific announced the successful passing of all resolutions at their recent Annual General Meeting, including the approval of financial statements, remuneration reports, and director re-elections. Notably, over 20% of shareholders opposed the re-election of Ralph Elman as a director, prompting the board to engage with shareholders for feedback. This outcome highlights the company’s commitment to stakeholder engagement and governance, potentially impacting its strategic direction and investor relations.

The most recent analyst rating on (GB:JDG) stock is a Buy with a £10600.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Business Operations and Strategy
Judges Scientific Strengthens Employee Incentives with Share Acquisition
Positive
May 13, 2025

Judges Scientific plc announced the acquisition of 655 ordinary shares at a price of 7820p per share, which were immediately allocated to employees as part of the company’s reward scheme. This move reflects the company’s ongoing commitment to rewarding its employees and maintaining a strong operational framework, potentially enhancing its market position and stakeholder confidence.

The most recent analyst rating on (GB:JDG) stock is a Buy with a £12230.00 price target. To see the full list of analyst forecasts on Judges Scientific stock, see the GB:JDG Stock Forecast page.

Business Operations and Strategy
Judges Scientific Executives Participate in Share Incentive Plan
Positive
May 8, 2025

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan involving several key executives, including the CEO, CFO, COO, Group Business Development Director, and Group Commercial Director. This transaction, conducted on the London Stock Exchange’s AIM Market, reflects the company’s ongoing commitment to aligning the interests of its management team with those of its shareholders, potentially enhancing stakeholder confidence and reinforcing its market position.

Shareholder MeetingsBusiness Operations and StrategyFinancial Disclosures
Judges Scientific Announces AGM Details and Annual Report Release
Positive
Apr 28, 2025

Judges Scientific plc has announced the posting of its Annual Report and Accounts along with the Notice of its Annual General Meeting (AGM), scheduled for May 22, 2025, at The Lansdowne Club in London. Shareholders are encouraged to attend the AGM in person or submit proxy votes online. This announcement underscores the company’s commitment to transparency and shareholder engagement, reflecting its strategic focus on sustainable growth and market presence in the scientific instrument sector.

Executive/Board ChangesBusiness Operations and Strategy
Judges Scientific Announces Board Changes and New Executive Committee
Positive
Apr 16, 2025

Judges Scientific has announced a significant change in its board and management structure, with Chief Operating Officer Mark Lavelle planning to retire by September 2026. As part of his transition, Lavelle will step down from the board in May 2025 but will continue to contribute to the group through a newly formed Executive Committee, which will oversee the management of the company. This restructuring aims to enhance the group’s operational and growth capabilities, ensuring continued success and development in the scientific instrument sector.

Business Operations and Strategy
Judges Scientific Executives Align Interests Through Share Purchases
Positive
Apr 8, 2025

Judges Scientific plc announced the purchase of ordinary shares by the Trustees of the Share Incentive Plan, involving several key executives including the CEO, CFO, COO, and other directors. This move, conducted on the London Stock Exchange’s AIM Market, reflects a strategic effort to align the interests of the company’s leadership with those of its shareholders, potentially strengthening stakeholder confidence and enhancing the company’s market positioning.

Business Operations and Strategy
Judges Scientific Director Increases Shareholding
Positive
Apr 7, 2025

Judges Scientific plc announced that Tim Prestidge, Group Business Development Director, purchased 511 ordinary shares in the company, increasing his holding to 564 shares. This transaction, conducted on the AIM market of the London Stock Exchange, reflects internal confidence in the company’s strategy and potential for growth, potentially impacting stakeholder perceptions positively.

Business Operations and StrategyFinancial Disclosures
Judges Scientific Confirms 2024 Financial Results
Positive
Apr 3, 2025

Judges Scientific plc has confirmed its full-year financial results for 2024, with no changes from the preliminary results published in March 2025. The company’s financial statements have been approved by the Board of Directors and audited, reinforcing its stable financial position and ongoing commitment to transparency. This announcement underscores Judges Scientific’s consistent performance and strategic focus on sustainable growth through acquisitions, which is likely to reassure stakeholders of its robust market positioning.

M&A TransactionsDividendsBusiness Operations and StrategyFinancial Disclosures
Judges Scientific Navigates Challenging 2024 with Strategic Acquisitions and Dividend Growth
Neutral
Mar 19, 2025

Judges Scientific plc reported a challenging trading year in 2024, with a 2% decrease in revenue and a 20% drop in adjusted operating profit, attributed to delays in a Geotek coring expedition and weaker order intake, particularly in China. Despite these challenges, the company completed three acquisitions and increased its cash conversion to normal levels. The year ended with a proposed final dividend increase of 10%, reflecting the company’s commitment to shareholder returns. Looking forward, Judges Scientific has commenced 2025 with a strong order book and expects performance to align with market expectations, bolstered by strategic acquisitions and a strengthened executive team.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.